

Otolaryngology – Head and Neck Tumor Board

Provided by Rutgers Robert Wood Johnson Medical School
Department of Otolaryngology – Head and Neck Surgery

10 Plum Street, 5th Floor, Conference Room
May 20, 2025. 7:30 AM – 8:30 AM

Craig Bollig, MD
Assistant Professor, Division of Head and Neck Oncologic Surgery

Taha Mur, MD
Assistant Professor, Division of Head and Neck Oncologic Surgery

Andrew Parrot, MD
Assistant Professor, Department of Pathology and Laboratory Medicine

Maurice FitzPatrick, MD
Assistant Professor, Department of Radiology

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Describe current and new management and prevention strategies used for various otolaryngologic diseases and patient types.
- Correlate the clinical presentation with pathologic, laboratory, and radiologic information and the pathophysiology of otolaryngologic diseases.
- Demonstrate understanding of current trends in otolaryngologic disease research that may be translated into improving patient care within clinical practice.

Target Audience

This activity is designed for healthcare practitioners in the fields of diagnostic radiology, surgery, internal medicine, neurological surgery, interventional radiology, plastic surgery, otolaryngology - head and neck surgery, dentistry, general nursing, oral and maxillofacial surgery and medical oncology.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Craig Bollig, MD, Taha Mur, MD, Andrew Parrot, MD, and Maurice FitzPatrick, MD have no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Kelvin Kwong, MD has the following relevant financial relationship with ineligible companies: Consultant: Smith & Nephew. P. Ashley Wackym, MD, Craig Bollig, MD, and Taha Mur, MD have no relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed have been mitigated.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.